HL-300 / Highlightll Pharma - LARVOL DELTA

HL-300 Ointment in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=156 | Recruiting | Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical Pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial. (PubMed, Expert Opin Investig Drugs) - "PK results showed slow percutaneous absorption, low systemic exposure after single dosing, and attainment of steady state with some accumulation after multiple dosing, while the overall safety profile remained acceptable. These findings support further phase II clinical development of HL-300 and provide a basis for dose optimization and efficacy evaluation in patients with AD and other inflammatory skin diseases."

Clinical • First-in-human • Journal • P1 data • PK/PD data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • JAK1 • JAK2 • JAK3 • TYK2

A Phase Ib/II Study of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=156 | Not yet recruiting | Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A single-center, randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability and pharmacokinetics of HL-300 ointment after single and multiple administration in healthy adult volunteers (ChiCTR) - P1 | N=36 | Completed | Sponsor: The Third Xiangya Hospital Central South University; The Third Xiangya Hospital Central South University

New P1 trial • Dermatitis • Dermatology • Immunology